Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with irinotecan as second-line treatment for extensive-stage small cell lung cancer
ChiCTR2100041921Phase 4Recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and irinotecan in small cell lung cancer (SCLC), sponsored by Baotou Cancer Hospital. Primary endpoints: objective response rate and quality of life. Started Feb 2021; status: recruiting.
02
Drugs
camrelizumabirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100041921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041921.